Department of Pharmaceutical Sciences, Vels Institute of Science, Technology & Advanced Studies (VISTAS), Chennai, Tamil Nadu, India
Antimicrobial resistance has become a serious worldwide health issue, undermining the efficacy of antibiotics and raising morbidity, mortality, and healthcare expenses across the globe. Antibiotic stewardship programs have been identified as critical measures to optimize the use of antimicrobials, enhance patient outcomes and reduce the emergence and transmission of resistant pathogens. This review offers an extensive perspective on antibiotic stewardship amidst the growing Anti microbial resistance, as it relates to critical concepts, clinical methods, and new technological developments. The main elements of stewardship the correct choice of antibiotic, dose, administration period and route, core elements of stewardship are talked about and key interventions like prospective audit and feedback, formulary restriction and de-escalation of therapy are addressed. The importance of rapid diagnostic tools, molecular methods, and point-of-care testing to facilitate the timely and targeted antimicrobial therapy is emphasized. Moreover, the introduction of artificial intelligence, machine learning, and genomic surveillance to stewardship systems is considered a disruptive solution to promote improved decision-making and surveillance of resistance. The review also considers the application of stewardship programs in various healthcare facilities, such as hospitals, intensive care units, outpatient, and long-term care facilities, where the focus has in the context-specific approaches. The need to incorporate an interdisciplinary approach that includes clinicians, pharmacists, microbiologists, nursing personnel, and educated patients is highlighted. Even though a lot has been done, the presence of resource constraints, uncertainty in diagnosis, behavioral issues, and lack of regulations continue to impede proper stewardship. To sum up, antibiotic stewardship will continue to be a key pillar in the fight against AMR and it will need long-term worldwide cooperation, innovation, and policy incentives. Combining innovative technologies and individualized solutions suggest opportunities to improve the results of stewardship and maintain the effectiveness of the current antimicrobial treatment in the new generations.
The concept of antibiotic stewardship has become an important aspect of contemporary healthcare, especially given the growing global epidemic of antimicrobial resistance (AMR). Antibiotics which were initially seen as miracle drugs revolutionizing the field of medicine by successfully combating previously deadly infections have since been beginning to lose their effectiveness as a result of the sheer volume of misuse, overuse, and lack of innovation in the development of antimicrobials [1]. Clinical, environmental and socio-economic factors have converged at an accelerated rate thereby increasing the emergence and spread of resistant pathogens which is a major threat to global health, food security and economic stability. Antibiotic stewardship program (ASP) is, in this case, a structured, evidence-based intervention that tries to maximize the utilization of antimicrobial agents to produce optimal clinical outcomes with minimal unwanted effects, such as toxicity, selection of pathogenic organisms, and the emergence of resistance [2]. A coordinated set of interventions aimed at enhancing and quantifying the correct utilization of antimicrobials may be described as antibiotic stewardship, which aims to facilitate the selection of the most appropriate drug regimen, including dose, duration of therapy, and route of delivery. It incorporates a multidisciplinary approach that involves clinicians, pharmacists, microbiologists, infection control specialists and policymakers who all collaborate to help in ensuring that antibiotics are used reasonably and in a prudent way. The essence of stewardship is not to limit the use of antibiotics but to make sure that patients are given the appropriate antibiotic, dose, time, and duration [3]. This idea is consistent with the principles of precision medicine, where individualized treatment is the priority, and it should be based on clinical evidence, microbiological information, and individual characteristics. Moreover, antibiotic stewardship is not confined to hospital environments to community healthcare settings, veterinary practice, and agriculture, which is indicative of AMR interconnectedness in One Health. The burden of antimicrobial resistance is immense globally and is ever increasing at an alarming rate [4]. Increased morbidity, mortality, longer hospitalization, and high costs of healthcare are linked to resistant infections. Millions of deaths are estimated to be associated with drug-resistant infections every year and it is predicted that AMR may be one of the major causes of mortality in the world unless urgent measures are taken. It is particularly heavier in low and middle-income nations, where healthcare systems are frequently underdeveloped, diagnostics are insufficient, and regulatory measures on antibiotics use are not as strict. Such environments often have antibiotics on the shelves and hence poor self-medication and improper course of treatment. Also, the widespread use of antibiotics in farm animals and agriculture leads to environmental reservoirs of resistance, which helps to transfer resistant genes between species and ecosystems. Travel and trade are also being globalized thus further increasing the rate of spread of resistant pathogens and AMR is indeed a transnational issue that needs a concerted global effort [5].
The pathways to antimicrobial resistance are both varied and intricate, including genetic mutations, horizontal gene transfer, and a process of selective pressure due to exposure to antibiotics Fig.1. Bacteria are able to develop resistance by enzyme degradation of antibiotics, changes in drug targets, high activity of efflux pumps, and low membrane permeability. These systems can be imprinted on mobile genetic components like plasmids, transposons and integrons so that resistance features can be quickly transferred among bacterial populations. The inappropriate use of antibiotics, including their use in the treatment of viral infections, in the case of unnecessary administration of broad-spectrum agents, or non-compliance with the recommended treatment regimens, produces a selective pressure in favor of the survival and multiplication of resistant strains [6]. As a result, infections that previously could be cured easily are hard to control, or even impossible to treat, and more toxic, or costly, or less efficient treatments must be used. Against this background, the reasons of having antibiotic stewardship programs are very strong and urgent. ASPs aim to implement changes in medical practice by focusing on the underlying causes of inappropriate antibiotic prescription by combining clinical guidelines, diagnostic tools, and educational programs. Lessening the needless exposure to antibiotics and, thus, lessening the selective pressure to slow down the development of resistance is one of the key aims of stewardship. This is done by having strategies like prospective audit and feedback, formulary restriction, preauthorization requirement and development of evidence based treatment protocols. Also, stewardship programs raise an awareness of the need to correctly and promptly diagnose, promoting the utilization of microbiological tests and rapid diagnostic technologies to inform specific therapy [7]. Identifying bacteria and viral infections and distinguishing between them, clinicians can prevent the irrational use of broad-spectrum antibiotics and use a more specific approach. Optimization of dosing regimens through pharmacodynamics and pharmacokinetic concepts is another important point of antibiotic stewardship. The correct dosage provides adequate levels of drugs to eliminate pathogens and reduce toxicity and chances of resistance. Drug monitoring Therapeutic drug monitoring can be used with some antibiotics to achieve optimum exposure especially in patients who are critically ill, or have altered metabolism. Moreover, stewardship initiatives support the de-escalation of treatment once pathogen identification and susceptibility information is accessible, to enable clinicians to replace broad-spectrum with narrow-spectrum agents. Clinically appropriate oral therapy conversion to intravenous therapy is also promoted as it lowers the healthcare expenses, decreases hospitalization, and enhances patient comfort without reducing the efficacy [8].
Fig.1: Mechanism of Antibiotic resistance
Antibiotic stewardship programs also involve the behavioral and cultural aspects that impact prescribing behavior. Clinicians can be faced with diagnostic ambiguity, time pressure, and patient expectations, potentially resulting in unneeded antibiotic prescriptions. The goal is to address these barriers by using education and training and development of clinical decision support systems as a means of stewardship. ASPs can enable healthcare providers to make informed decisions that are in line with best practices by instilling a culture of accountability and continuous quality improvement [9]. The education of patients also plays a crucial role because raising awareness about the dangers of antibiotic overuse may decrease the number of prescriptions that are not necessary and encourage patients to adhere to the treatment plan. Though the advantages of antibiotic stewardship are undeniable, there are a number of obstacles that impede its implementation and success. The barriers to implementing comprehensive stewardship programs can be resource constraints especially in low- and middle-income nations. The short supply of trained individuals, insufficient laboratory facilities, and access to diagnostic equipment are also major challenges that need to be overcome with the help of capacity-building programs and global cooperation [10]. As well, the differences in healthcare systems, regulatory affairs, and cultural practices require the implementation of stewardship to be done in specific contexts. The opposition to change by the healthcare provider and the lack of institutional assistance may further complicate the process of intertwining stewardship with the everyday practice [11]. These issues can only be mitigated by effective leadership, policy commitment and long-term investment in healthcare infrastructure and manpower development. This review aims to conduct an in-depth review of antibiotic stewardship in the era of antimicrobial resistance, emphasizing the main strategies that can address the problem of effective treatment and mitigation of resistance [12]. It seeks to integrate the existing evidence on stewardship interventions, diagnostic developments and policy frameworks that facilitate optimal use of antibiotics. Exploring the importance of multidisciplinary teamwork and new technologies, this review aims to find new ways of improving the performance of stewardship programs in various healthcare facilities. Moreover, it discusses the difficulties and possibilities of introducing stewardship programs in resource-scarce settings, where solutions need to be flexible and able to scale up [13-15].
Overview of Antimicrobial resistance
Antimicrobial resistance (AMR) has become one of the most challenging phenomena to the overall health of the global population in the 21st century, threatening decades of advances in the management of infectious diseases [16]. It is a characteristic of microorganisms such as bacteria, viruses, fungi and parasites which survive and multiply in the presence of antimicrobial agents that were once effective against them. Among them, the most important issue of concern is bacterial resistance to antibiotics as it is highly prevalent and it has direct effects on clinical outcomes. The emergence and transmission of AMR is a multifactorial phenomenon that is caused by biological, clinical, environmental, and socio-economic factors. The knowledge of how it develops resistance, the drivers that enable it to develop, and its epidemiology patterns is critical in coming up with effective measures to alleviate its effects [17]. The processes of antimicrobial resistance development are complicated and are both intrinsic and acquired. Intrinsic resistance is an inherent property of some species of bacteria, and it develops as a result of inherent structural or functional properties that make the bacteria resistant to certain antibiotics. As an example, the outer membrane of Gram-negative bacteria is a permeability barrier that restricts the effect of several antimicrobial agents. Conversely, acquired resistance is caused by genetic alterations which make organisms previously sensitive to antimicrobial exposure resistant [18]. These mutations may take place spontaneously via mutations in the genes in chromosomes, or through horizontal gene transfer (HGT), as a result of which the bacteria can obtain resistance genes in other organisms. HGT can be through transformation, transduction, and conjugation, which can be mediated by mobile genetic elements including plasmids, transposons and integrons. On a molecular scale, there are a number of important mechanisms that promote antibiotic resistance. Among the most frequent is enzymatic degradation or alteration of the drug, such as the formation of β-lactamases that break down β-lactam antibiotics, making them useless [19]. The other mechanism is through changes in the antibiotic target site that include mutations in the penicillin binding proteins or ribosomal subunits that diminish drug binding affinity. Another significant resistance mechanism is efflux pumps that actively eject antibiotics out of the bacterial cell and, therefore, reduce intracellular drug levels. Also, antibiotic into the cell can be restricted by changes in membrane permeability, which is usually caused by alterations in porin proteins. Biofilm formation also makes it difficult to treat by providing a protective environment that increases bacterial survival and allows the survival of populations resistant to treatment [20]. The mechanisms frequently coexist in one organism and result in multidrug resistance (MDR) and extensively drug-resistant (XDR) phenotypes, which are challenging to treat. Causes of antimicrobial resistance are multifaceted and linked, encompassing clinical, agricultural, and environmental aspects. Misprescription in clinical practices is a significant cause of AMR. Among them are the treatment of viral infections with antibiotics, unjustified broad-spectrum treatment, incorrect dosage, and extended treatment. Uncertainty in diagnosis and the absence of quick and precise diagnostic assays usually drive clinicians to prescribe empirical therapy, which might not be optimized to the causative pathogen [21]. Factors related to patients like non-compliance with the prescribed regimens and self-medication also contribute to the problem. In most areas, antibiotics are easily sold over the counter, making it easy to abuse and overuse them. Another important cause of AMR is the agricultural sector, where antibiotics have been extensively used to promote growth and prevent diseases in animals. It is a practice that exerts selective pressure in favor of the emergence of resistant bacteria, which may be transferred to humans either through direct contact, ingestion of food or via the environment [22].
Antimicrobials use in aquaculture also leads to resistance in aquatic ecosystems and therefore there is a need to adopt a holistic One Health approach to understanding human, animal, and environmental health due to the interconnectedness of these components of health. The environmental factors are also important in the spread of resistance. Pharmaceutical waste, hospital effluents, and agricultural runoff push antibiotics and resistant microorganisms into the soil and water systems, forming reservoirs of resistance genes, which may be transferred throughout microbial communities [23]. Poor sanitation, urbanization and poor disposal of waste also contribute to the propagation of resistant pathogens especially in crowded places. Antimicrobial resistance is an epidemic that is highly geographically diverse and dynamic over time. The high-income nations have put in place strong surveillance and stewardship measures, which have assisted in containing some of the resistant pathogens but resistance has still been a major challenge in these environments. Conversely, the AMR is disproportionately impacting low- and middle-income countries (LMICs) because of the lack of healthcare facilities, poor infection control, and weak regulation. Multidrug-resistant organisms, including methicillin-resistant Staphylococcus aureus (MRSA), extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae, and carbapenem-resistant Acinetobacter baumannii, have become more common worldwide, making treatment choices more challenging and causing more treatment failures. Globalization has also contributed to greater transmission of resistant pathogens since international travel and trade make it easier to transfer microorganisms easily across the borders. Resistant infections outbreaks can swiftly evolve into transnational, which highlights the significance of international surveillance and response measures. The development of molecular epidemiology and genomic sequencing has improved the capacity to monitor the evolution and spread of resistance, and it offers meaningful information on the dynamics of transmission and informs interventions. Nevertheless, differences in surveillance ability of the regions restrict access to comprehensive data, which prevents the realization of complete understanding and remedy of the global burden of AMR [24]. The consequences of antimicrobial resistance are far-reaching, with implications on morbidity, mortality, and healthcare systems. Resistant infections are linked with severe disease, the length of illness, and the possibility of complications. The patients having resistant infections also need to spend more time in the hospital, receive more intensive treatment, and use second- or third-line treatment that might be less effective, more toxic and more costly. This has not only an individual patient outcome but also a heavy burden on health care systems especially in resource-constrained environments. The economic consequences of AMR are enormous, including both direct healthcare expenditures, including cost of hospitalization and treatment; indirect expenses, including productivity loss and workforce involvement. The mortality rate has been observed to be very high in cases of resistant infections than in cases of susceptible organisms. As an example, infections of the bloodstream by the carbapenem-resistant organisms have been linked with the mortality rates that are higher than 40-50 percent in certain environments. The fact that pan-resistant strains, against which no known effective antibiotics exist, are becoming more and more common is raising alarm about the possibility of a post-antibiotic world, where everyday illnesses and minor injuries would once again be fatal. In addition, AMR jeopardizes the effectiveness of contemporary medical practice that depends on the efficacy of antimicrobial prophylaxis, such as surgery, organ transplant, cancer chemotherapy, and neonatal care. These situations might lead to decades of medical advances being reversed just because it is difficult to prevent and treat infections [25].
Efflux pumps are embedded systems on membranes that force the antibiotics and other poisonous substances out of the microbial cells, thus reducing the concentrations of drugs in the intracellular space to sub-therapeutic concentrations. This decreases the intracellular exposure, leading to antibiotics not reaching or maintaining effective binding to their targets, and thus a decrease in bactericidal or bacteriostatic effect. The efflux-mediated resistance is especially significant in that it can be used to confer low to moderate levels of resistance to a wide range of structurally unrelated antibiotics and it can also synergize with other resistance mechanisms like reduced permeability and target modification.
The bacterial efflux pumps have widely been grouped into various superfamilies according to their structure, source of energy and mode of transport. These are the Resistance Nodulation Division family, the Major Facilitator Superfamily, the ATP-Binding Cassette transporters, the Small Multidrug Resistance (SMR) family and the Multidrug and Toxic Compound Extrusion family. Amongst the most clinically relevant types of pumps are RND pumps, which are common in Gram-negative bacteria, and which expel a broad range of antibiotics, such as β-lactams, fluoroquinolones, and tetracyclines. They are generally tripartite systems that span the inner membrane, periplasm, and the outer membrane (e.g., AcrAB -TolC), and can directly extrudate drugs into the external environment. The energy that powers efflux activity differs among the families. The proton motive force is usually involved in RND, MFS, SMR, and MATE transporters, where drug export is linked to proton influx, but not in ABC transporters, which use ATP hydrolysis. This energy dependence enables unlimited and rapid release of antibiotics despite high extracellular levels of drugs. Resistance can also be significantly increased by overexpression of efflux pump genes, which can be caused by mutations in regulatory elements or global stress responses. Moreover, efflux systems can be coded on mobile genetic elements, which can be horizontally transferred between bacterial populations. Efflux pumps lead to intrinsic and acquired and adaptive resistance. Upregulation of efflux systems is often linked in clinical isolates with multidrug-resistant phenotypes. Notably, efflux activity has the potential to lower intracellular antibiotics levels to subinhibitory levels, facilitating the subsequent selection of further mutations and biofilm formation, which just further complicates treatment. Therapeutically, efflux pump inhibitors are under investigation as adjuvant therapy to reinstate the action of antibiotics, but their use in clinical practice has not been fully realized because of specificity, toxicity and pharmacokinetic issues. To conclude, efflux pump-mediated resistance is an important and multifaceted mode of bacterial resistance to antimicrobials. The wide range of substrate recognition, energy-driven efficiency, and ability to control genetic regulations make it a central target of future antimicrobial strategies and stewardship interventions Fig.2.
Fig.2: Mechanism of antibiotic resistance via efflux pump
Principles of Antibiotic Stewardship
Antibiotic stewardship is an evidence-based method of overseeing the use of antimicrobials in a systematic manner with the two-fold aim of enhancing patient outcomes and reducing the development of antimicrobial resistance (AMR). The basis of stewardship rests in rational selection and use of antibiotics based on clinical judgment, microbiological information and pharmacological factors [26]. These principles are implemented in the form of structured stewardship programs which foster accountability, ongoing monitoring and interdisciplinary working. Through prudent utilization of antibiotics, stewardship programs not only maximize treatment outcome but also minimize adverse drug events, medical expenses and the pressure of selection that promotes the development of resistance. The main components of the antibiotic stewardship programs (ASPs) give a guideline on how to implement them in various healthcare environments effectively. These aspects normally encompass the leadership commitment, accountability, drug expertise, action, tracking, reporting, and education. Leadership commitment is needed to mobilize the required resources such as staff, infrastructure, and the technological backup to continue with stewardship practices. Responsibility should be built by appointment of a health care professional, usually an infectious disease doctor or a clinical pharmacist, who monitors the activities and achievement of the program [27]. Trained experts who possess specialized knowledge in antimicrobial pharmacotherapy offer expertise in drugs, and prescribing decisions made are evidence-based and consistent with best practices. Action is defined as the application of specific interventions, including prospective audit with feedback, formulary restriction, and guideline development, to optimize the use of antibiotics. Monitoring and reporting systems can be used to follow the patterns of antibiotic prescription, resistance and clinical outcomes, allowing the use of the obtained data. The principles of stewardship are further reinforced through education and training of healthcare providers and patients to create awareness and compliance with proper prescribing behavior [28]. One of the key principles of antibiotic stewardship is the right drug, right dose, right duration, and right route paradigm, where accuracy of antimicrobial treatment is stressed. The choice of the right antibiotic will be informed by the suspected or confirmed pathogen, the site of infection, patient specificity and local resistance patterns. Empirical therapy is frequently started in acute environments, but should be guided by evidence based recommendations and customized to reduce the needless coverage of broad-spectrum therapy. Optimization of dose is also of equal importance because under-dosing can result in treatment failure and treatment resistance and over-dose can cause toxicity. The principles of pharmacokinetics and pharmacodynamics (PK/PD) are crucial in the process of establishing the best dosing schedule especially in patients who are critically ill or in patients with impaired pharmacokinetics. Antibiotic therapy must be as brief as possible to reach a clinical resolution since this may lead to resistance and alter normal microbiota. On the same note, the route of administration must be chosen according to clinical necessity but preferably oral therapy should be used when possible to minimise hospitalization, expense, and complications that come with intravenous therapy [29]. The de-escalation and simplification of the antibiotic treatment is one of the approaches on a stewardship program that seeks to optimize treatment depending on changing clinical and microbiological data. De-escalation is a process whereby the spectrum of antimicrobial coverage is minimized after the causative pathogen and its susceptibility profile are known. The method minimizes selective pressure created by broad-spectrum antibiotics and collateral damage to the host microbiome [30].
Streamlining can also involve the elimination of unnecessary antibiotics, replacement of combination therapy with monotherapy and improved dosing schedules. These plans necessitate strict observation of patient reaction, lab findings and clinical signs so that the effectiveness of treatment can be maintained without undue exposure. The successful shift between empirical to targeted therapy is a characteristic of strong stewardship and indicates the combination of diagnostic information with clinical decision-making [31]. Due to the development of microbiological and molecular technologies, the role of diagnostics in antibiotic stewardship has been gaining more and more significance. The correct and timely diagnosis is vital in identifying bacterial and non-bacterial infections, therefore avoiding unnecessary use of antibiotics. Although regarded as the gold standard, traditional culture-based approaches can be time-consuming and slow down targeted therapy. The development of many fast diagnostic methods, such as polymerase chain reaction (PCR), mass spectrometry, and point-of-care testing, has greatly improved the capability to detect the pathogens and the resistance markers in a shorter period of time. Such technologies help clinicians to start the relevant therapy sooner and limit the use of broad-spectrum antibiotics based on trial and error. In addition, biomarkers like procalcitonin and C-reactive protein can be useful in determining the chances of bacterial infection and in determining the decision to initiate or stop taking antibiotics. The related element of antibiotic stewardship is known as diagnostic stewardship that is interested in the correct usage of diagnostic tests and effectiveness in making clinical decisions [32]. This involves choosing the appropriate test and the appropriate patient at the appropriate time and as well as decoding the results in order to make appropriate decisions in therapy. Excessive or improper use of diagnostic tests may cause false-positives, unneeded medical intervention, and higher medical expenditure. On the other hand, over-investment in diagnostics can lead to late or inadequate treatment. The combination of diagnostic data with clinical judgment and the local epidemiological trends will increase the accuracy of antimicrobial prescribing and contribute to the overall objectives of stewardship programs. Besides improvement in technology, clinical decision support system (CDSS) and electronic health records (EHRs) have emerged as useful tools in enhancing the principles of stewardship. Such systems may offer real-time instructions on the choice of antibiotic, dosage, and the length of treatment, or warnings about a possible drug interaction or a lack of adherence to the existing guidelines [33]. CDSS will increase the consistency and quality of antimicrobial prescribing practices by enabling evidence-based decision-making. To sum up, the concepts of antibiotic stewardship offer a holistic approach to the optimization of antimicrobial use and fighting the increasing risks of antimicrobial resistance. Following the main program components, following the principles of proper drug choice and use, using the principles of de-escalation, and using the power of diagnostic innovations, healthcare systems can provide better patient outcomes, and keep the existing antibiotics effective. Stewardship should not just be considered as a duty, but also as an obligation to make sure that the antimicrobial treatment continues to be successful against the ongoing resistance challenges [34].
The basis of antimicrobial therapy lies in the ability to selectively disrupt important microbial processes at the minimum harm to the host and at the maximum harm to the pathogen. The major action mechanisms include cell wall synthesis inhibition, protein synthesis, nucleic acid replication and transcription, critical metabolic pathways, and cell membrane integrity changes. Effective resistance mitigation and treatment is based on strategic implementation of the following mechanisms; implemented in accordance with pharmacokinetic/pharmacodynamic (PK/PD) principles, pathogen susceptibility, and site of infection. Suppression of the cell wall synthesis is one of the cornerstone strategies, especially in the case of bacteria with peptidoglycan. The β-lactams attach to penicillin-binding proteins, preventing transpeptidation, causing cell lysis; glycopeptides prevent cross-linking of peptidoglycans at another stage. Protein synthesis inhibitors attack the ribosomal 30S or 50S subunits, disrupting translation; they include aminoglycosides (mRNA misreading), tetracyclines (tRNA binding), macrolides, lincosamides, and oxazolidinones (peptide elongation or initiation). Nucleic acid-directed agents, e.g. fluoroquinolones, rifamycins, disrupt the DNA gyrase/topoisomerase activity or RNA polymerase, respectively, halting the replication and transcription. Antimetabolites (e.g., folate pathway inhibitors) disrupt key biosynthetic pathways, and membrane-active agents disrupt permeability and cellular homeostasis. Much more than the choice of mechanism-specific drugs, therapeutic strategies entail the optimization of regimens. PK/PD-informed dosing is intended to meet the exposure goals related to efficacy: time greater than minimum inhibitory concentration (T>MIC) when time-dependent agents are used, peak-to-MIC ratios (Cmax/MIC) when concentration-dependent drugs are used. The optimization of the dose is especially important in patients who are critically ill and who may have physiological changes that can alter distribution and clearance. Combination therapy is employed strategically to extend empirical coverage, synergistic killing and prevent the development of resistance. As a case in point, intracellular penetration and bactericidal activity can be increased by combining a cell wall active agent with a protein synthesis inhibitor. Culturally and susceptibility-based de-escalation is necessary to tailor therapy to the most effective range, with minimal collateral damage to the microbiota. Other stewardship-consistent interventions are proper choice of route, preferring intravenous administration of severe infections after which the oral therapy should be administered as early as possible, and the treatment should be as short as possible. Rapid diagnostics integration can allow an earlier identification of the pathogen and specific treatment minimizing the use of broad-spectrum therapy. Lastly, host factors, penetration of the site of infection, and biofilm activity are taken into consideration to make informed decisions about drug selection and regimen Fig.3.
Fig: 3 Mechanisms of antimicrobial therapy strategies
Stewardship strategies in clinical practice
Effective application of antibiotic stewardship programs in clinical practice depends on a set of specific, evidence-based measures that are aimed at maximization of the antimicrobial use and preservation of high-quality patient care standards. The strategies are designed in such a way that it could affect prescribing behavior, enhance therapeutic outcomes, and curb the occurrence and transmission of antimicrobial resistance. Combining clinical knowledge, microbiological information, and institutional practices, stewardship interventions establish an interactive framework that can facilitate rational use of antibiotics in a variety of healthcare facilities [35]. Some of the best strategies include prospective audit and feedback, formulary restriction and preauthorization, guidelines and protocol development, dose optimization with therapeutic drug monitoring, and intravenous-to-oral switch strategies. Prospective audit and feedback is a foundation of clinical stewardship, which entails a systematic review of antimicrobial prescriptions and then direct, personalized feedback to prescribers. This approach allows steward teams (usually comprising infectious disease specialists, clinical pharmacists, and microbiologists) to determine the suitability of current antibiotic treatment on the basis of clinical features, microbiological findings and patient-specific factors. Constructive and educative feedback is given, and prescribers are encouraged to make changes to therapy where needed, including de-escalating broad-spectrum antibiotics, changing dosing or stopping unwarranted treatment [36]. Prospective audit and feedback maintains prescriber autonomy, unlike restrictive methods, and encourages accountability and ongoing learning. It has demonstrated a considerable positive effect on prescribing practice allowing to decrease the use of inappropriate antibiotics and increase compliance with evidence-based practices. This approach also creates a culture of collaboration and trust between stewardship teams and frontline clinicians, essential to the success of the program in the long term. Formulary restriction and preauthorization are more directive forms of stewardship in attempt to restrain the use of particular high-risk or broad-spectrum antibiotics. In this method, there are groupings of antimicrobial agents which are classified as restricted and cannot be prescribed without first obtaining the permission of an authorized member of a stewardship team [37]. This makes sure that these agents are only administered when there is clinical need, and it limits unwarranted exposure, as well as selective pressure towards resistance. Institutional policies usually inform the preauthorization processes with the help of clinical criteria that describe the proper use [38]. Although this strategy is very effective in preventing the use of targeted antibiotics and cost containment, it should be introduced cautiously so as not to delay treatment especially among patients who are critically ill. To alleviate these risks, most institutions utilize hybrid models, which have both preauthorization and post-prescription review, which ensure that both access to therapy in time is achieved and continuous monitoring. To balance the advantages of restriction and the necessity of timely and proper patient care, effective communication, clear guidelines, and timely decision-making are necessary [39].
Clinical guidelines and protocols are crucial in standardizing the antimicrobial prescribing practice and are essential in guaranteeing consistency in care delivery. Evidence-based guidelines have been structured to assist clinicians with the diagnosis and treatment of infectious diseases, antibiotic selection, and dosage, duration of use, and route of administration. The guidelines are often specific to local epidemiology, local resistance patterns and are therefore very relevant to the local health care environment [40]. Algorithms related to decision-making and clinical pathways can also be integrated into protocols to support quick and precise decision-making, especially in stressful settings like emergency departments and intensive care units. Guidelines built into electronic health systems also make them more accessible and usable, and enable real-time clinical decision support. Guidelines should be regularly updated and audited to make sure that they are consistent with new evidence and changing patterns of resistance. Guidelines and protocols are important in enhancing the outcome of treatments and reducing the use of inappropriate antibiotics because they help to reduce variability in prescribing practices [41]. Two key elements of stewardship are dose optimization and therapeutic drug monitoring, which guarantee the administration of antibiotics at the optimal levels to guarantee maximum efficacy and minimal toxicity and resistance development. Pharmacokinetic (PK) and pharmacodynamic (PD) principles guide the process of dose optimization by describing the relationship between antimicrobial activity and drug exposure. Age, weight, organ functioning, and illness severity of the patient are the factors that should be taken into consideration when defining dosing regimens [42]. Physiological alteration can cause major changes in drug distribution and clearance in critically ill patients, which require the use of personalized dosing. Therapeutic drug monitoring refers to the process of measuring the levels of drugs in the body fluids in order to ascertain that the desired levels are reached and maintained. This is especially critical when using antibiotics with narrow therapeutic indices, like aminoglycosides or glycopeptides, when inappropriate dosing results in treatment failure or toxicity. TDM improves the safety and efficacy of antimicrobial treatment by allowing adjustment of the dose with precision and complements the larger of stewardship efforts [43]. Another important intervention is intravenous-to-oral switch strategies, which facilitate the reasonable use of antibiotics by changing patients, who are on parenteral therapy to oral therapy, when it is clinically suitable. The idea behind this method is that most infections can be treated successfully using oral antibiotics as soon as the patient is clinically stable, can take oral medications, and is beginning to improve. The IV to PO switch avoids the hazards of intravenous therapy like catheter related infections and thrombophlebitis and also reduces the cost of healthcare and reduces hospitalization [44]. It improves patient comfort and increases the possibility of discharge, helping to improve resource use and patient satisfaction. To effectively execute this strategy, it must have clear eligibility criteria, such as hemodynamic stability, the positive effect on clinical parameters, and access to appropriate oral formulations and adequate bioavailability. Stewardship teams are frequently actively involved in the process of candidate identification towards IV-to-PO conversion, as well as offer advice to treating clinicians [45].
Together, these stewardship interventions comprise a multidimensional and holistic approach to the optimal utilization of antimicrobials in clinical care. They require a concerted effort, active involvement of interprofessional healthcare providers, and ongoing monitoring to be effective. Although both strategies possess their own distinct advantages, their implementation in a single stewardship model has the greatest impact and sustainability [46]. Resource shortages, clinical practice variability, and resistance to change are some of the challenges that need to be addressed with the help of education, leadership support, and innovative technologies. Finally, the use of such measures is critical to maintaining the effectiveness of available antibiotics, enhancing patient outcomes and overcoming the international burden of antimicrobial resistance.
Role of Rapid Diagnostics and Emerging Technologies
Infectious disease management has shifted because of the implementation of rapid diagnostics and new technologies into antibiotic stewardship programs (ASP) that allow making timely, accurate, and evidence-based decisions regarding treatment. The conventional diagnostic tools, especially, culture-based tools, may take quite a long time to yield results and this may lead to delayed targeted therapy, and the empirical use of broad-spectrum antibiotics [47]. This latency has a major role in improper use of antimicrobials and increases the emergence of antimicrobial resistance (AMR). Conversely, fast diagnostic assays and high-tech platforms offer clinicians actionable information in a much shorter period of time, allowing the identification of pathogens early, detection of resistance, and optimization of antimicrobial treatment. These innovations can not only improve clinical outcomes but also contribute significantly to the decrease of unjustified exposure to antibiotics and the overall performance of the health care systems. Molecular diagnostic methods have become a pillar in quick detection of pathogens and profiling of resistance [48]. Polymerase chain reaction (PCR), multiplex PCR panels, nucleic acid amplification tests (NAATs), and next-generation sequencing (NGS) can be used to detect microbial pathogens and resistance genes on clinical specimen with high sensitivity and specificity. In comparison to the traditional culture techniques, where 24-72 hours or more may be required, molecular diagnostics can provide the results in hours, enabling prompt commencement of specific treatment. As an example, a certain resistance determinant, e.g., mecA in methicillin-resistant Staphylococcus aureus (MRSA), or genes encoding extended-spectrum β-lactamases (ESBLs) can be identified using PCR-based methods, thus informing the correct choice of antibiotics [49]. Next-generation sequencing also extends diagnostic capacities as it offers the detailed genomic data, allowing the discovery of new resistance mechanisms and outbreak investigations. Although they have merits, cost, infrastructure and technical expertise should be considerate when introducing molecular diagnostics especially in resource constrained environments [50].
Another important innovation in diagnostic stewardship is point-of-care testing (POCT) with its ability to provide rapid testing services to patients at the bedside or in an outpatient environment. The POCT devices are intended to offer real-time results (in minutes) and therefore allow clinicians to make real-time decisions on antimicrobial therapy. The tests are especially useful in distinguishing between bacterial and viral infections, thus decreasing the prescriptions of unnecessary antibiotics [51]. As an example, the rapid antigen detection test of respiratory pathogens and biomarkers like procalcitonin and C-reactive protein can help to decide the possibility of bacteria infection and to start or stop using antibiotics. POCT devices are very convenient to use in primary care, emergency department, and remote or underserved due to their portability, ease of use, and low level of training. Nevertheless, it is vital to achieve the accuracy, quality control and proper interpretation of POCT results to maximize their clinical utility and avoid misuse. Artificial intelligence and machine learning use in antibiotic stewardship is a revolutionary method of maximizing the utilization of antimicrobials based on the use of data to make decisions [52]. The AI algorithms can be used to process huge volumes of clinical, microbiological, and epidemiological data and produce predictive models to assist with diagnosis, risk-stratification, and treatment choices. An example is that machine learning models are able to forecast the probability of infection with resistant organisms basing on patient history, comorbidities, previous exposure to antibiotics, and local resistance patterns. Such understandings will empower clinicians to choose the most suitable empirical therapy and reduce unnecessary broad-spectrum coverage [53]. Also, the clinical decision support systems powered by AI and embedded into electronic health records (EHRs) can offer real-time guidance on antibiotic choice, dosage, and duration, as well as notifications of possible drug interactions or noncompliance with the current guidelines. Natural language processing complements these systems and helps to extract pertinent information in unstructured clinical notes, making decision support more accurate and comprehensive. Although AI and ML have great potential, their effective application involves effective data infrastructure, predictive model validation, and attention to ethical and regulatory aspects, such as data privacy and algorithm transparency [54].
Genomic surveillance and integration of big data have gained significance in the local and global levels in the understanding and combating of antimicrobial resistance. The development of both whole-genome sequencing and bioinformatics tools have made it possible to characterize microbial genomes in detail, thus offering insights into the evolution, transmission, and distribution of resistance genes [55]. Genomic surveillance enables tracking of outbreaks, high-risk clones, and monitoring of resistance trends against time. These genomic insights when combined with big data analytics may be combined with clinical and epidemiological data to inform the public health strategies and inform stewardship interventions. As an illustration, the investigation of big data sets provided by the hospital networks and national surveillance systems can provide insights into the trends of antibiotic use and resistance and can be used to create specific policies and interventions. The use of cloud-based platforms and data-sharing programs also promotes cooperation between institutions and countries, ensuring compatibility in responding to AMR. The implementation of these new technologies in antibiotic stewardship programmes needs to be multidisciplinary and to involve clinical skills, laboratory facilities and information technology infrastructure [56]. Healthcare professionals should be trained and educated to enable the proper use and interpretation of diagnostic and technological tools. Furthermore, cost-effectiveness studies and implementation research are required to determine the effect of these technologies on clinical outcomes, resistance patterns and healthcare costs. The innovative elements that can assist in filling the gap and increasing access to advanced technologies in the resource-limited environment include portable diagnostic devices, telemedicine, and simplified data platforms. Finally, the speed of diagnostics and new technologies have tremendously boosted the ability of antibiotic stewardship programs to provide accurate, timely, and effective antimicrobial care [57]. These innovations are important in reducing the inappropriate use of antibiotics and the transmission of antimicrobial resistance by ensuring early detection of the pathogen, directing specific treatment, and supporting the decision making process based on data. Further development and applications of molecular diagnostics, point-of-care testing, artificial intelligence, and genomic surveillance will be critical in the future of infectious disease management and the sustainability of antimicrobial therapy in the context of emerging resistance issues [58].
Antibiotic Stewardship in Different Healthcare settings
To be the most effective, antibiotic stewardship programs need to be designed to meet the unique requirements, issues, and available resources of the particular healthcare environment. The heterogeneity of patient groups, patterns of infections, prescribing patterns, and infrastructure capabilities of healthcare settings require situational stewardship approaches. The main principles of stewardship, which include the use of the right antibiotics, dose, time, and monitoring, are similar in all hospitals, intensive care units, outpatient and community health care and in long-term care settings [59]. The entire and flexible strategy is required in order to make sure that stewardship interventions are practical and effective in these diverse contexts. The most established and organized type of ASPs is the form of hospital-based stewardship programs, which is normally adopted in tertiary care institutions and large healthcare facilities [60]. These initiatives are multidisciplinary, which means that they include infectious disease specialists, clinical pharmacists, microbiologists, infection control practitioners and hospital administrators. Ascentivated primary located in hospitals are governed by formal policies, dedicated staff, and have access to sophisticated diagnostic and informational systems. Some of the critical interventions are prospective audit and feedback, formulary restriction, guideline development and integration of clinical decision support system in the electronic health records. Another advantage of hospitals is strong microbiological laboratories, which will deliver suitable culture and susceptibility information in time, allowing specific therapy and de-escalation [61]. Monitoring of antimicrobial use and resistance trends is an ongoing activity, which permits the constant assessment and outcome improvement of the stewardship measures. Nonetheless, implementation may be complicated by issues like high patient turnover, a complicated mix of cases, and the necessity to make decisions fast, which may demand effective coordination and a robust institutional foundation. The antimicrobial resistance in intensive care units (ICUs) is highly dangerous and risky because of the severity of the disease, the frequent presence of invasive equipment, and the presence of multidrug-resistant organisms. Broad-spectrum antibiotic therapy is a common practice in ICUs because the patient is in urgent need of treatment and because it is not known what is causing the illness. This enhances the chances of improper use of antibiotics and the development of resistance [62]. The concept of stewardship in the ICUs is aimed at finding a balance between the necessity to provide prompt and life-saving treatment and the concept of rational antibiotic use. The strategies involve early introduction of suitable empirical therapy and subsequent de-escalation depending on microbiological data, introduction of antibiotic time-outs to reassess continuing therapy, and biomarker use, e.g., procalcitonin to determine duration of therapy. The optimization of dosing is especially paramount in patients in the ICU since they have altered pharmacokinetics related to critical illness, and require personalized dosing and therapeutic drug measurements. Strict hand hygiene, environmental cleaning, and monitoring of healthcare-associated infections are part of the infection prevention and control measures in stewardship in ICUs. Even, with these measures, high burden of resistant pathogens and complexity of ICU care remain a major challenge [63].
Antibiotic stewardship in outpatient and community settings has unique challenges associated with the prescribing practices, patient expectations, and the lack of access to diagnostic tools. In these facilities, a large percentage of antibiotic prescriptions are given out in situations that are usually caused by viruses like upper respiratory tract infections, where there is no clinical advantage of antibiotics. This misuse is motivated by factors like uncertainty in diagnosis, time, and perceived patient demand [64]. Community-based interventions on stewardship involve education, dispersion of guidelines and advocacy of delayed prescribing programs, where the prescription of antibiotics is only done when the symptoms persist or get worse. Education of the population becomes an important measure to decrease the patient-centered demand of antibiotics and enhance compliance with the prescribed treatment. Point-of-care testing and clinical scoring systems can help clinicians differentiate between bacterial and viral infections, which will aid in making more rational prescriptions. Also, regulatory policies to limit over-the-counter prescription of the antibiotics are also important in curbing abuse in most parts. There are new opportunities to implement stewardship interventions in communities, especially in underserved communities, using digital health tools, such as telemedicine and mobile health applications [65]. Another important location where antibiotic stewardship is critical is long-term care facilities such as nursing homes and rehabilitation centers that are vulnerable because of their who are usually elderly, multimorbid, and at a higher risk of infections. The use of antibiotics in LTCFs is often empirical and can be started by nonspecific symptoms, which results in overuse and improper prescribing. The shortage of on-site diagnostic services and the use of external labs might slow down the process of timely diagnosis and specific treatment. LTCFs focus more on facility specific guidelines, education of their staff, and standard criteria of starting antibiotics, including the Loeb minimum criteria of infection diagnosis [66]. Regularly reviewing antibiotic prescriptions, following resistance trends and working interprofessionally with other healthcare providers are key elements of stewardship in these environments. The infection prevention strategies, such as vaccination, hand hygiene, and environmental sanitation, are also critical in lowering the rates of infection and consequential antibiotics. Limited resources, staffing, and clinical expertise variability are frequent challenges to the implementation of stewardship programs in LTCFs, requiring simplified and scalable strategies [67-70].
In all healthcare facilities, the effectiveness of antibiotic stewardship programs relies on proper communication, interdisciplinary cooperation, and ongoing education of healthcare professionals and patients. The use of technological devices and policy-making frameworks to incorporate stewardship principles into the daily workflow of a clinic improves their sustainability and effectiveness. Interventions should be tailored to the needs and limitations of each setting so that stewardship activities can be both possible and effective [71]. In addition, the One Health approach that acknowledges the interconnections between the human, animal, and environmental health is a vital approach in solving the antimicrobial resistance problem in a holistic manner. Finally, antibiotic stewardship should be applied in the full range of healthcare delivery, and strategies should be modified to address the specifics of each environment and its opportunities and risks. The programs in hospitals are structured and resource intensive to offer stewardship and ICUs need specialized interventions to deal with high risk and critically ill patients. Both community environments and long-term care facilities need educational and behavioral interventions to minimize inappropriate prescribing, and simplified, guideline-based interventions to vulnerable populations are needed. With such a diversity of settings, harmonizing stewardship activities can optimize antimicrobial use, enhance patient outcomes, and reduce the global threat of antimicrobial resistance [72].
Interdisciplinary approach to Stewardship
A well-coordinated interdisciplinary strategy, incorporating the knowledge and cooperation of various healthcare professionals, as well as active patient engagement and awareness campaigns, is essential to the success of antibiotic stewardship programs. Antimicrobial resistance is a complex issue, and no single prescribing practice can be applied to tackle it, so a systems-based approach to align clinical decision-making, microbiological knowledge, pharmaceutical stewardship, infection control, and patient behavior is needed [73]. Through interdisciplinary collaboration, stewardship programs can guarantee holistic management of antimicrobial utilization, improve the quality of care, and sustainable practices, which reduce the emergence and dissemination of resistance. Clinicians and specialists in the field of infectious diseases are at the forefront of antibiotic stewardship because they are the ones who identify infections and start antimicrobial treatment. Their clinical judgment plays a critical role in deciding whether antibiotics are needed, the type of empirical therapy to provide and altering the treatment according to patient response and diagnostic results [74]. The infectious disease specialists offer highly qualified skills and knowledge on handling complicated infections, interpreting microbiological information, and de-escalation. They are also involved in the formulation of institutional guidelines, involve themselves in prospective audit and feedback programs and promote education and training programs. These professionals are able to make antimicrobial therapy effective and judicious by incorporating evidence-based practices in their clinical practice. Pharmacists and clinical microbiologists are also essential to the stewardship framework, as they offer expertise to support clinical decision-making. Clinical pharmacists are also used in the optimization of dosing, monitoring of therapeutic drugs and determining possible drug interaction or adverse effects [75]. Their pharmacodynamics and pharmacokinetics allow the personalization of antibiotic regimens to patient needs, especially in complicated patients like the critically ill or immunocompromised patient. Pharmacists also have a significant role to play in the implementation of formulary restrictions, prescription review and in educating healthcare providers about the appropriate use of antimicrobials. On the other hand, it is the duty of clinical microbiologists to identify the pathogens accurately and the antimicrobial susceptibility patterns. Their work guides targeted therapy and aids in monitoring resistance trends in healthcare facilities. Close cooperation between microbiology laboratories and clinical teams is necessary to integrate microbiological data into clinical practice to de-escalate and optimize therapy in a timely manner. Infection control teams and nursing staff play a crucial role in the success of antibiotic stewardship programs because they directly participate in the work with patients and the introduction of infection prevention measures [76]. A significant role of nurses is the administration of antibiotics, the control of patient responses, and the identification of adverse effects. They are also an important connection among patients and the rest of the medical team, offering the means of communication and compliance with the treatment plan. Infection control teams have the role of applying measures to stop the spread of resistant organisms including hand hygiene measures, cleaning of the environment, isolation measures and monitoring of healthcare-associated infections. These measures indirectly reduce the use of antibiotics by lowering the occurrence of infections, and these strategies promote the goals of stewardship. It is necessary to continue training and involve nursing personnel in the ongoing process to ensure high standards of infection control and to support the principles of stewardship in practical work [77-80].
Educating patients and raising awareness about it is an essential part of a comprehensive stewardship approach, as it tackles the behavioural and social aspects that lead to the misuse of antibiotics. Patients tend to shape the prescribing choice due to their expectations and perception of treatment; therefore, there is a need to give clear and correct information regarding the right use of antibiotics [81]. The educational programs must focus on the difference between bacterial and viral infection, the necessity to follow the prescribed regimen, and the risks of not using antibiotics in case of unneeded treatment, such as resistance and side effects. Information can be distributed using publicity campaigns, community outreach programs, online platforms, among other means to encourage responsible antibiotic use on a greater scale. Educating patients will not only lessen the need to prescribe patients unnecessary medications but also help them feel a sense of collective responsibility in the fight against AMR [82].
Challenges and barriers to antibiotic stewardship
Although the advantages of antibiotic stewardship programs are well-known in maximizing antimicrobial utilization and addressing antimicrobial resistance (AMR), their successful application is limited by various systemic, clinical, and socio-economic obstacles. The restriction of resources is one of the most critical obstacles, especially in the low- and middle-income countries (LMICs) where the infrastructure and trained staff as well as diagnostic opportunities are insufficient in many cases. Lack of microbiological labs, inaccessibility to quick diagnostic resources, and lack of funding complicate the possibility of enacting comprehensive stewardship interventions. Aspirational sustainability and institutional commitment of ASPs can be constrained despite well-resourced environments due to competing healthcare priorities and budgets. Another issue that is critical and affects the prescribing behavior is diagnostic uncertainty. Clinical practice in most clinical scenarios, especially in acute care and emergency situations, requires clinicians to start empirical antibiotic treatment without certain microbiological validation. This will in most cases result in the application of broad-spectrum antibiotics, which although they may be life-saving, they contribute to the emergence of resistance in times of improper application or when taken over extended periods. This is further complicated by the resistant time in acquiring culture and sensitivity leading to timely de-escalation of therapy. New rapid diagnostic technologies have emerged; however, their accessibility, cost, and incorporation into a regular clinical activity vary. There are also behavioral and cultural aspects, which significantly restrict the functionality of stewardship activities. Unnecessary or excessive use of antibiotics is the rule rather than the exception as prescribers, clinical failure phobia, and perceived patient expectations drive this habit. Patient pressures in outpatient and community healthcare settings can put clinicians in a situation where they are asked to prescribe antibiotics, especially viral infections, contrary to best practice. Moreover, the misuse is aggravated by the use of antibiotics, which are available over the counter and self-administered in most territories. The unwillingness of healthcare professionals to change and the lack of proper training and awareness only contribute to a lack of adherence to stewardship guidelines. The implementation of antibiotic stewardship is also influenced by regulatory and policy-related issues. The varying stewardship practices in the regions are due to inconsistent enforcement of the antibiotic prescribing regulations, absence of standardized national policies and inadequate surveillance systems. Lack of effective antimicrobial use and resistance monitoring systems restricts tracking of trends, measuring interventions and policy decision making. Moreover, human health, veterinary, and environmental sectors are not always well-coordinated to support the effectiveness of the One Health approach to AMR.
Barriers affecting stewardship also include technological and data-related barriers. Although electronic health records and clinical decision support system have the potential to improve antimicrobial prescribing, they are often implemented in a piecemeal manner, and interoperability challenges can constrain their use. Standardization, data quality, and real-time accessibility have been a problem especially in resource constrained environments. Moreover, the adoption of state-of-the-art technologies like artificial intelligence demand significant infrastructure, authentication, and regulatory control. In summary, a complicated combination of resource demands, diagnostic limitation, behavioral determinants, regulatory loopholes, and technology issues impedes the successful implementation of antibiotic stewardship programs. To overcome these barriers, a complex solution is needed which involves investing in the healthcare infrastructure, increasing the diagnostic capacity, training and behavioral change, reinforcing regulatory systems and enhancing international cooperation. To make the stewardship effective and sustainable, it is necessary to overcome these challenges so that the increasing menace of antimicrobial resistance could be diminished.
CONCLUSION AND FUTURE PERSPECTIVES
Antimicrobial resistance (AMR) is one of the most urgent contemporary health issues of the world at large that threatens to erode decades of medical advances and jeopardize the efficacy of life-saving treatments. The concept of antibiotic stewardship has become an important approach to this crisis by enhancing the rational use of antimicrobials, improving patient outcomes, and decreasing the selective pressure that fuels the rise and dissemination of resistant pathogens. Stewardship programs have shown great potential in terms of maximizing antimicrobial therapy in various health care settings through the combination of evidence-based prescribing practices, multidisciplinary collaboration, and sophisticated diagnostic tools. Nevertheless, the ongoing occurrence and increased spread of AMR highlights the necessity of long-term efforts, novelty, and international collaboration. The effective use of antibiotic stewardship programs has underscored the need to have a systematic and flexible framework that integrates clinical decisions with microbiological information, pharmacologic concepts, and hospital policies. Prospective audit and feedback, formulary restriction, dose optimization, and de-escalation are core strategies that have been found to be effective to reduce inappropriate antibiotic usage and enhance therapeutic outcomes. Additionally, the rapid diagnostics and the introduction of new technologies have increased the accuracy and timeliness of antimicrobial therapy, allowing clinicians to shift towards targeting treatment more effectively. Regardless of these developments, resource and infrastructure gaps, as well as lack of awareness, remain the major obstacles to the successful implementation and success of stewardship projects, especially in the low- and middle-income nations. Going forward, the future of antibiotic stewardship is in the combination of new technology, personalized medicine, and world-wide collaborative models. Artificial intelligence and machine learning have significant potential to change the antimicrobial prescribing process through the availability of predictive analytics, real-time decision support, and optimization of treatment plans in line with the patient-specific and epidemiological data. Such technologies may improve the precision of the diagnosis process, detect the trends of resistance, and assist in designing custom therapeutic strategies that reduce the needless exposure to antibiotics. In a similar fashion, genomic surveillance and the integration of big data will enable the tracking of resistance patterns, prompt identification of outbreaks, and targeted public health actions. It is also necessary to develop new antimicrobial agents and alternative therapeutic approaches to supplement stewardship efforts. With the shortage of new antibiotics in pipeline, there is an increasing attention to the exploration of new strategies, including bacteriophage therapy, antimicrobial peptides, immunotherapy, and microbiome modulation. These solutions have the possibility to bypass normal resistance mechanisms and offer successful treatment solutions to multidrug-resistant infections. Also, the idea of precision medicine in infectious diseases, when treatment is informed by patient-specific features, pathogen genomics, and host immune responses, is a paradigm shift, which has the potential to considerably improve the efficacy and safety of antimicrobial therapy. Another important part of the future stewardship work is the strengthening of global and national policies. The introduction of uniform guidelines, effective surveillance mechanisms, and regulatory policies is important to make sure that all sectors use antibiotics responsibly and consistently. One Health approach, which acknowledges the interdependence between human, animal and environmental health, should be incorporated fully in stewardship strategies to tackle the multihazardous nature of AMR.
This involves controlling the use of antibiotics in farms, enhancing sanitation and waste disposal as well as encouraging responsible behavior in the food production chain. Education and awareness will remain a key factor in determining the future of antibiotic stewardship. Digital health platforms, telemedicine, and mobile apps provide new channels to communicate with the population and implement stewardship interventions among underserved communities. To sum up, antibiotic stewardship is an essential aspect of the international response to antimicrobial resistance, as it will provide the opportunity to sustain the effectiveness of the available antibiotics and enhance patient care. The successful combination of technological innovation, policy development, interdisciplinary collaboration, and involvement of people will determine the future of stewardship. Addressing existing threats and capitalizing on new opportunities, one can reduce the effects of AMR and protect the efficiency of antimicrobial treatment in the future generations. All these efforts must be continued at the local, national and global levels in order to make stewardship efforts dynamic, resilient and responsive to changes in the infectious disease landscape.
REFERENCES
Defin D V, Abitha P, V K Mohammed Naazil, Antibiotic Stewardship in the Era of Antimicrobial Resistance: Strategies for Effective Treatment, Int. J. of Pharm. Sci., 2026, Vol 4, Issue 4, 3274-3299. https://doi.org/10.5281/zenodo.19674126
10.5281/zenodo.19674126
